Shots:
- Waiv has collaborated with Daiichi Sankyo to lead digital pathology biomarker discovery for an ADC program, leveraging its end-to-end computational pathology platform
- Waiv will use its platform to analyze early-phase trial data, incl. tumor microenvironment profiling across H&E & IHC slides, biomarker discovery, & outcome prediction, aimed at identifying biomarkers of treatment response
- The platform leverages foundation models trained on hundreds of thousands of images to develop AI models for data-constrained settings, extracting predictive signals from H&E & IHC slides, identifying novel histopathological biomarkers, & delivering interpretable outputs for clinical decisions
Ref: Businesswire | Image: Waiv & Daiichi Sankyo | Press Release
Related News: Interna Therapeutics Collaborates with Daiichi Sankyo to Develop MNM-Based Targeted Delivery Technologies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
